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Objectives
Vitamin D is commonly prescribed in primary care
for the prevention and treatment of deficiency and
for maintenance after treatment (although supple-
mentation for maintenance and prevention can be
bought over-the-counter). There is wide variation
in the costs to the NHS in England of oral prepar-
ations of vitamin D, even for a single-specific
dose and route.1 It is possible that the availability
of multiple options for the same intended medicine,
the costs of which are unlikely to be known by the
prescriber, could result in an inadvertent excess
spend. We aimed to estimate the annual cost-
saving if only the cheapest vitamin D preparations
were prescribed.
Design
Primary care prescribing data for 2018 were down-
loaded from NHS Digital (https://digital.nhs.uk).2
Monthly datasets include the number of items, quan-
tity and cost of each drug prescribed and dispensed.
Private prescriptions are not recorded. All prescrip-
tion items relating to the vitamin D preparations cole-
calciferol and ergocalciferol, regardless of dose, route
or manufacturer, were extracted. Data for each spe-
cific preparation were aggregated across all practices
and all months to give the annual number of items
and their cost across England. All liquid and inject-
able preparations were assumed to be appropriately
prescribed and therefore excluded from the analysis.
Combined preparations – such as calcium/vitamin D,
calcium/alendronate and multivitamins – were also
excluded. For each defined dose range of vitamin D,
the lowest cost preparation was identified, and the
potential cost-savings if only these preparations
were prescribed was calculated.
Setting
Primary care in England.
Participants
All patients registered with a general practitioner in
England in 2018.
Main Outcome Measure
The difference between actual and potential spend on
vitamin D prescriptions, if only the lowest priced
preparation were available.
Results
In 2018, over 4 million vitamin D items were pre-
scribed in primary care, at a cost of over £21 million.
If only the cheapest options were prescribed for non-
liquid preparations across all dose ranges, and assum-
ing all prescriptions were appropriate, it would have
resulted in an approximate £15 million (>70%) cost-
saving to the NHS. Maintenance doses of vitamin D
(designated as 800 to 2000 international units per day
as per NICE guidelines3) accounted for more than
half of the spend (£12 million). It was noted that
all the cheapest options available are suitable for
vegetarians.
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The prescribing of more expensive vitamin D prepar-
ations in primary care may have significant financial
consequences, although our results relate to a single
year of prescribing within NHS primary care. Since
choice of preparation may intentionally be based on
factors other than cost (e.g. dietary requirements, bio-
availability, what was initially prescribed by a hos-
pital), work is needed nationally to rationalise
available prescribing options. If national guidance
were produced, the difficulties of implementation
within individual Clinical Commissioning Groups
might limit economic benefit. National efficient pro-
curement strategies are an alternative approach, but
require careful consideration of legislative frame-
works (such as the Public Contract Regulations
20154) with safeguards to prevent horizontal cooper-
ation between suppliers.
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